Effects of estrogen replacement therapy on the lipoprotein profile in postmenopausal women with ESRD

Kidney International

Volumn 54, Issue 4, 1998, Pages 1344-1350

  Ginsburg, Elizabeth S ^b   Walsh, Brian ^b   Greenberg, Louise ^b   Price, Deborah ^b   Chertow, Glenn M ^b   Owen Jr , William F ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NONE

Author keywords

Cardiovascular disease; Cholesterol; End stage renal disease; Estrogen; Lipids; Lipoproteins; Menopause

Indexed keywords

APOLIPOPROTEIN A1; CHOLESTEROL; ESTRADIOL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT INDICATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0031682919     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1998.00087.x     Document Type: Article

References (67)

1. ROSTAND SG, KIRK KA, RUTSKY EA: Relationship of coronary risk factors to hemodialysis-associated ischemic heart disease. Kidney Int 22:304-308, 1982
2. NATIONAL CENTER FOR HEALTH STATISTICS: Health, United States, 1990. Hyattsville, Public Health Service, 1991
3. US RENAL DATA SYSTEM: USRDS 1990 Animal Data Report. Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1990
4. LINDER A, CJARRA B, SHERRARD D, SCRIBNER BH: Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 290:697-701, 1974
5. GREEN D, STONE NJ, KRUMLOVSKY A: Putative atherogenic factors in patients with chronic renal failure. Prog Cardiov Dis 62:133-144, 1983
6. FOLEY RN, PARFREY PS, HARNETT JD, KENT GM, MARTIN CJ, MURRAY DC, BARRE PE: Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 47:186-192, 1995
7. ATTMAN P-O, ALAUPOVIC P: Lipid abnormalities in chronic renal insufficiency. Kidney Int 39(Suppl):S16-S32, 1991
8. APPEL. G: Lipid abnormalities in renal disease. Kidney Int 39:169-183, 1991
9. WANNER C, FROMMHERZ K, HORL WH: Hyperlipoproteinemia in chronic renal failure: Pathophysiological and therapeutic aspects. Cardioloiy 78:202-217, 1991
10. PARRA HJ, MEXDOUR H, CACHERA C, DRACON M, TACOUTE A, FRUCHART JC: Lp(a) lipoprotein in patients with chronic renal failure treated by hemodialysis. (abstract) Clin Chem 33:721, 1987
11. HAFFNER SM, GRUBRE KK, ALDRETE G, MORALES PA, STERN MP, TUTTLE KR: Increased lipoprotein (a) concentrations in chronic renal failure. J Am Soc Nephrol 3:1156-1162, 1992
12. CRESSMAN MD, HEYKA RJ, PAGANINI EP, O'NEAL J, SKIBINSKI CI, HOFF HF: Lipoprotein (a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 86:475-482, 1992
13. KAYSEN GA: Hyperlipidemia of chronic renal failure. Blood Purif 12:60-67, 1994
14. KOSTNER GM, AVOGARO P, CAZZOLATO E, MARTH E, BITTOLO-BON G. QUINCI GB: Lipoprotein Lp (a) and the risk for myocardial infarction. Atherosclerosis 38:51-61, 1986
15. RHOADS GG, DAHLEN G, BERG, K, MORTON NE, DANNENBERG AL: Lp(a) lipoprotein as risk factor for myocardial infarction. J Am Med Assoc 256:2540-2544, 1986
16. HOFF HF, BECK GJ, SKIBINSKI CI, JURGENS G, O'NIEL, J. KRAMRE J, LYTLE B: Serum Lp (a) level as a predictor of vein graft stenosis after coronary bypass surgery in patients. Circulation 77:2138-1244, 1988
17. SCANU AM, FLESS GM: Lipoprotein (a): Heterogeneity and biological relevance. J Clin Invest 85:1709-1715, 1990
18. SAND KAMP M, FUNKE H, SCHULTE H, KOHLER E, ASSMANN G: Lipoprotein (a) is an independent risk factor for myocardial infarction at a young age. Clin Chem 36:20-23, 1990
19. PONTICELLI C, BARBI G, CATALUPPI A, DONATI C, ANNONI G, BRANCACCI D: Lipid abnormalities in maintenance dialysis patients and renal transplant recipients. Kidney Int 13:572-578, 1978
20. VINCENTI F, AMEND WJ, ABELE J, FEDUSKA NJ, SALVATIERRA O: The role of hypertension in hemodialysis-associated atherosclerosis. Am J Med 68:363-369, 1980
21. The Lipid Research Clinics' Population Studies Data Book. The Prevalence Study. Bethesda, US Department of Health and Human Services. Public Health Service, National Institutes of Health, NIH Publication No. 80-1572, 1908
22. SACHS FM, WALSH BW: The effects of reproductive hormones on serum lipoproteins: Unresolved issues in biology and clinical practive. Ann NY Acad Sci 592:272-285, 1990
23. KIM HJ, KALKHOFF RK: Changes in lipoprotein composition during the menstrual cycle. Metabolism 28:663-668, 1979
24. MATTSON LA, SILFVERSTOIPE G, SAMSOIE G: Lipid composition of serum lipoproteins in relation to gonadal hormones during the normal menstrual cycle. Eur J Obstet Gynecol Reprod Biol 17:327-335, 1984
25. WALSH BW, SCHIFF I, ROSNER B, GREENBERG, L. RAVNIKAR V, SACKS FM: Effects of postmenopausal estrogen replacement of the concentrations and metabolism of plasma lipoproteins N Engl J Med 325: 1196-1204, 1991
26. FARISH E, HART DM, GRAY CE, BEASTALL G, FLETCHER CD, LINSAY R: Effects of treatment with oestradiol levonorgestrel on bone, lipoproteins and hormone status in postmenopausal women. Clin Endocrinol 31:607-615, 1989
27. SOMA M, MESCHIA M, GHANEM K: Plasma Lp (a) concentration after oestrogen and progestagen in postmenopausal women. (letter) Lancet 337:612, 1991
28. HENRIKSSON P, ANGELIN B, BERGLUND L: Hormonal regulation of serum Lp (a) levels. Opposite effects after estrogen treatment and orchidectomy in males with prostate carcinoma. J Clin Invest 89:1166-1171, 1992
29. WALSH BW, SACHS FM: The effects of low dose oral contraceptives on very-low density and low density lipoprotein metabolism. J Clin Invest 91:2126-2132, 1993
30. KANNEL WB, HJORTLANP M, MCNAMARA PM, GORDON T: Menopause and risk of cardiovascular disease. The Framingham Study. Ann Int Med 85:447-452, 1976
31. GORDON T, KANNEL WB, HJORTLAND MD, McNAMATA PM: Menopause and risk of cardiovascular disease. The Framingham Study. Ann Int Med 89:157-161, 1978
32. HENDERSON BE, RSS RK, PAGANINI-HILL A, MACK TM: Estrogen use and cardiovascular disease. Am J Obstet Gynecol 154:1181-1186, 1986
33. BUSH TL, BARRITT-CONNOR E, COWAN LD: Cardiovascular mortality and noncontraceptive use of estrogen in women: Results from the Lipid Research Clinic Program Follow-up Study. Circulation 75:1102-1109, 1987
34. STAMPFER MJ, COLDITZ GA, WILLETT WC: Postmenopausal estrogen therapy and cardiovascular disease: Ten year follow-up from the Nurses' Health Study. N Engl J Med 325:756-762, 1991
35. BACKORIK PS, ALBERS JJ: Precipitation methods for quantification of lipoproteins, in Plasma Lipoproteins (part B. vol 129), Methods in Enzymology, edited by ALBERS JJ, SFGREST JP, Orlando, Academic Press, 1986, pp 78-100
36. FINLEY PR, WILLIAMS JR, BYERS JM: Immunochemical determination of human immunoglobulins with a centrifugal analyzer. Clin Chem 22:1037-1041, 1976
37. WANNER C, FROMMERZ K, HORL WH: Hyperlipoproteinemia in chronic renal failure. Pathphysiological and therapeutic aspects. Cardiology 78:2020-2027, 1991
38. MANNINEN V, ELO MO, FRICK MH: Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. J Am Med Assoc 260:641-651, 1988
39. CATTRAN DC, FENTON SSA, WILSON DR, STEINER G: Defective triglyceride removal in lipemia associated with peritoneal dialysis and haemodialysis. Ann Int Med 85:29-33, 1476
40. GINSNURG E, OWEN WF, GREENBERG LM, SHEA BF, LAZARUS JM, WALSH B: Estrogen absorption and metabolism in postmenopausal women with end stage renal disease. J Clin Endo Metab 81:4414-4417, 1996
41. STAMPFER MJ, COLDITZ GA, WILLETT WC: Postmenopausal estrogen therapy and cardiovascular disease. Ten year follow-up from the Nurses' Health Study. N Engl Med 325:756-762, 1991
42. SULLIVAN JM, VANDER ZWAAG R, HUGHES JP, MADDOCK V, KROETZ FW, RAMANATHAN KB, MIKIVIS DM: Estrogen replacement and coronary artery disease. Effect on survival in postmenopausal women. Arch Intern Med 150:2557-2562, 1990
43. ELISAF MS, DARDAMANIS MA, PAPAGALANIS ND, SIAMOPOULOS KC: Lipid abnormalities in chronic uremic patients. Response to treatment with gemfibrozil. Scand J Urol Nephrol 27:101-108, 1993
44. FIORINI F, PATRONE E, CASTELLUCCIO A: Clinical investigation on the hypolipidemic effect of simvastatin versus prohucol in hemodialysis patients. Clin Ther 145:213-217, 1994
45. CORONEL F. TORNERO F, TORRENTE J, NAKANJO P, DE OLEO P, MACIA M, BARRIENTOS A: Treatment of hyperlipidemia in diabetic patients on dialysis with a physiological substance. Am J Nephrol 11:32-36, 1991
46. BOSCH T, THIERY J, GURLAND HJ, SEIDEL D: Long-term efficiency, biocompatibility, and clinical safety of combined simultaneous LDL-apheresis and haemodialysis in patients with hypercholcsterolaemia and end-stage renal failure. Nephrol Dial Transplant 8:1350-1358, 1993
47. WANNER C, HORL WH, LULRY CH, WILLAND H: Effects of HMg-CoA rEductase inhibitors in hypercholesterolemic patients on hemodialysis. Kidney Int 39:754-760, 1991
48. WAHLOVISI ML, HURLEY BP: Hyperlipoproteinemia and dietary fat modification in haemodialysis and renal transplant patients. Med J Aust 2:207-208, 1977
49. COLLINS P, ROSANO GM, SARREL PM, ULRICH L, ADAMOPOULOS S, BEALE CM, MCNEILL JG, POOLE-WILSON PA: 17-beta estradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease. Circulation 92:24-30, 1995
50. rd: Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation 89:2545-2551, 1994
51. FELSON DT, SHANG Y, HANNAN MT: The effect of postmenopausal eslrogen therapy on bone density in elderly women. N Engl J Med 329;1141-1146, 1993
52. CAULEY JA, SEELEY DG, ENSRUD K: Estrogen replacement therapy and fractures in older women. Ann Intern Med 122:9-16, 1995
53. CARR BR, MACDONALD PC: Estrogen treatment of postmenopausal women. Adv Intern Med 28:491, 1983
54. HENRY K, PIERARD-FRANCHIMONT C, CAUWENBERGH G, PIERARD GE: Age related changes in facial skin contours and rheology. J Am Geriatr Soc 45:220-222, 1997
55. DUNN LB, DAMESYN M, MOORE AA, REUBEN DB, GREENDALE GA: Does estrogen prevent skin aging? Results from the first National Health and Nutrition Examination Survey (NHANES 1). Arch Dermatol 133:339-342, 1997
56. SHERWIN BB: Hormones, mood, and cognitive function in postmenopausal women. Obstet Gynecol 87(Suppl):20S-26S, 1996
57. HONJO J, TANAKA K, KASHIWAGI T, URABE M, OKADA H, HAYASHI M, HAYASHI K: Senile dementia-Alzheimer's type and estrogen. Horm Metab Res 27:204-207, 1995
58. KAWAS C, RESNIK S, MORRISON A: A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: The Baltimore Longitudinal Study of Aging. Neurology 48:1517-1521, 1997
59. BARRETT-CONNOR, KRITZ-SILVERSTEIN D: Estrogen replacement therapy and cognitive function in older women. JAMA 269:2637-2641, 1993
60. LIVIO M, MANNUCCHI PM, BIGNANO G: Conjugated estrogens for the management of bleeding associated with renal failure. N Engl J Med 315:731, 1986
61. LOHR JW, SCHWAB SJ: Minimizing hemorrhagic complications in dialysis patients. (abstract) J Am Soc Nephrol 2:961, 1991
62. COLDITZ GA, HANKINSON SE, HUNTER DJ: The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 332:1589-1593, 1995
63. BERGKVIST L, ADAMI H-O, PERSSON I: The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl Med 321:293-297, 1989
64. JICK H, DERBY LE, MYERS MW, VASILAKIS C, NEWTON KM: Risk of hospital admission tor idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 348:981-983, 1996
65. BOSTON COLLABORATIVE DRUG SURVEILLANCE PROGRAM: Surgically confirmed gallbladder disease, venous thromboembolism, and breast tumors in relation to postmenopausal estrogen therapy. N Engl J Med 290:15-19, 1974
66. KESSLER CM, SZYMANSKI LM, SHAMSIPOUR Z, MUESING RA, MILLER VT, LAROSA JC: Estrogen replacement therapy and coagulation: Relationship to lipid and lipoprotein changes. Obstet Gynecol 89:326-331, 1997
67. SCARABIN PY, ALHENC-GELAS M, PLU-BUREAU G, TAISNE P, AGHER R, AIACH M: Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Throm Vasc Biol 17:3071-3078, 1997